Clinical Scorecard: Roswell Park Set to Open Several New Trials this Year for Innovative CAR T-Cell Therapies

At a Glance

Key Highlights

• New CAR T-cell trials targeting CD19, CD3, and CD83 for B-cell malignancies and AML
• Innovative CAR T-cells engineered to resist hostile tumor microenvironments, including cytokine expression
• First-in-human trials exclusively at Roswell Park, including trials for ovarian and hepatocellular carcinoma
• Collaboration with industry partners for advanced CAR T-cell therapies

Guideline-Based Recommendations

Diagnosis

• Identify patients with relapsed or refractory B-cell malignancies and solid tumors, including specific antigens.

Management

• Utilize innovative CAR T-cell therapies targeting specific antigens, including engineered cytokine expression.

Monitoring & Follow-up

• Assess patient response and persistence of CAR T-cells in clinical trials, including monitoring for exhaustion.

Risks

• Potential for adverse effects related to CAR T-cell therapy and tumor microenvironment interactions.

Patient & Prescribing Data

Patients with relapsed or refractory cancers, including those not eligible for standard CAR T-cell products.

CAR T-cells with optimized signaling domains and cytokine expression may offer improved outcomes in resistant cancers.

Clinical Best Practices

• Conduct thorough patient eligibility assessments for CAR T-cell trials, including specific antigen targeting.
• Monitor for signs of CAR T-cell exhaustion and tumor microenvironment resistance, including cytokine interactions.
• Engage in multidisciplinary collaboration for trial development and patient management, emphasizing innovative approaches.

References

• Roswell Park Comprehensive Cancer Center